



4 May 2021

ASX ANNOUNCEMENT

ACC Abstract Demonstrates Potential of SOZO in Heart Failure

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health today announced the publication of an HF-Dex™ abstract that was accepted for poster presentation at the American College of Cardiology (ACC) 70th Virtual Annual Scientific Session on 15-17 May 2021. The abstract was published online in the *Journal of the American College of Cardiology Abstract Supplement*.

The recently published paper, *Clinical Utility of Fluid Volume Assessment in Heart Failure Patients Using Bioimpedance Spectroscopy*, established the potential clinical utility when a heart failure patient's HF-Dex™ level exceeded 51%, Extracellular Fluid expressed as a percentage of Total Body Water (ECF%TBW). It concluded that this information may be a clinically relevant aid for physicians in clinical risk stratification and fluid volume monitoring of heart failure patients.

Today's ACC abstract demonstrates the potential value of the SOZO® HF-Dex measure.

The abstract, titled "Bioimpedance Spectroscopy Measurement of Ongoing Fluid Overload Post-Discharge from Hospitalization for Decompensated Heart Failure," showed the following:

- **Heart failure patients with HF-Dex over 51% at the time of hospital discharge are 4.25 times more likely to be readmitted to hospital within 45 days of heart failure than patients with HF-Dex below 51%.** This difference was statistically significant with a P value of 0.0472.
- **Of the 10 patients readmitted for heart failure, 70% of them had a discharge HF-Dex level over 51%.** This corresponds to an odds ratio of 4.25 (95% CI: 1.02 to 17.7, P=0.0472)
- Overall, 7 of 35 (20%) patients with HF-Dex levels over 51% on discharge were readmitted compared to only 3 of 54 (5.7%) patients with HF-Dex levels below 51%.
- The conclusion from the abstract states that HF-Dex measurements near the time of hospital discharge may help identify individuals at higher risk for readmission and may benefit from closer follow-up to reduce the likelihood of readmission.

This is a significant finding, as the cost of hospital readmissions is enormous, costing the US healthcare system an estimated \$31 billion annually, and hospitals must cover the cost of readmissions in the first 30 days of discharge. Additionally, Medicare fines hospitals for high readmission rates with 82% of hospitals in the program receiving readmissions penalties in 2019. **A study conducted by the Agency for Healthcare Research and Quality (AHRQ) on readmissions from 2011 identified congestive heart failure as the top cause of readmissions among Medicare patients with nearly 1 in 4 readmitted within 30 days.**

"After a heart failure related hospital stay, patients may experience improvement in symptoms even though fluid overload persists," said Annie Burns, ACNP, lead author of the abstract. "This analysis shows that SOZO with HF-Dex has the potential to identify patients with fluid overload, who are at higher risk of readmission at the time of hospital discharge and would benefit from closer follow-up," she continued.

The American College of Cardiology is the premier professional society for cardiology with more than 54,000 members. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, offers cardiovascular accreditation to hospitals and institutions, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications.

“The ACC annual meeting is the leading scientific session for US cardiology and has global reach,” commented Richard Carreon, Managing Director and CEO of ImpediMed. “Presenting data here provides important validation for our technology and its potential to integrate into existing patient care pathways for the reduction of hospital readmissions. The data from this abstract is significant and it demonstrates that established normative range data gathered by using SOZO can be very useful in risk stratifying patients.”

View the HF-Dex poster abstract:

<https://www.abstractsonline.com/pp8/#!/9228/presentation/22547>

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Communications

T: +61 3 8866 1200

E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO® Digital Health Platform

SOZO is a point-of-care assessment tool to guide clinical decision-making and maximise patient health. Using ImpediMed's bioimpedance spectroscopy (BIS) technology, SOZO measures and tracks critical information about the human body to aid clinicians in providing proactive patient care including early detection of disease progression, treatment monitoring, risk stratification, and patient education. SOZO is non-invasive, fast, and easy to use. Results from the 30-second test are available immediately on the device and online. ImpediMed's HiTrust certified cloud provides secure data aggregation, analytics, and reporting that can be customised to individual practices. There are over 700 SOZO devices in use globally.

For more information, visit: <https://www.impedimed.com/products/sozo/>

About SOZO HF-Dex™ Analysis for Heart Failure

The SOZO fluid analysis for heart failure provides an objective measure of fluid levels in heart failure patients. It utilises ImpediMed's HF-Dex heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented together with reference ranges for normal fluid volumes. When used as part of a clinical assessment of patients living with heart failure, SOZO helps differentiate between fluid and tissue-related weight changes.

For more information, visit: <https://www.impedimed.com/healthcare/heart-failure/>

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.